Ultima Genomics, Inc., a developer of ultra-high-throughput sequencing systems, today announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected the UG200 Series as the ...
The global DNA sequencing market is projected to reach USD 40.02 billion by 2031, driven by declining sequencing costs, expanding clinical applications in oncology and rare diseases, and growing ...
Companies unite in shared vision of enabling researchers to translate genomic insights to groundbreaking discoveries Partnership includes launch of new IDT xGen™ NGS products designed exclusively for ...
Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
Ultima Genomics, Inc., a developer of ultra-high-throughput sequencing systems, continues its mission to enable sequencing at scale with the unveiling of the UG200 Series and next generation Solaris 2 ...
Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people each year and caused an | Genetics And Genomics ...
PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected PacBio HiFi ...
IDT's suite of NGS innovations aim to tackle longstanding bottlenecks in library preparation, targeted enrichment, and whole genome analysis.
A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...
FORT DETRICK, Md. – Researchers at the U.S. Army Medical Research Institute of Infectious Diseases are testing a promising new biological threat detection method in high-fidelity training scenarios, ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results